CN110652527A - Magnesium sulfate oral liquid - Google Patents
Magnesium sulfate oral liquid Download PDFInfo
- Publication number
- CN110652527A CN110652527A CN201911030657.1A CN201911030657A CN110652527A CN 110652527 A CN110652527 A CN 110652527A CN 201911030657 A CN201911030657 A CN 201911030657A CN 110652527 A CN110652527 A CN 110652527A
- Authority
- CN
- China
- Prior art keywords
- magnesium sulfate
- oral liquid
- percent
- essence
- sulfate oral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 title claims abstract description 166
- 229910052943 magnesium sulfate Inorganic materials 0.000 title claims abstract description 83
- 235000019341 magnesium sulphate Nutrition 0.000 title claims abstract description 83
- 239000007788 liquid Substances 0.000 title claims abstract description 57
- 239000004376 Sucralose Substances 0.000 claims abstract description 18
- 235000003599 food sweetener Nutrition 0.000 claims abstract description 18
- 235000019408 sucralose Nutrition 0.000 claims abstract description 18
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical group O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims abstract description 18
- 239000003765 sweetening agent Substances 0.000 claims abstract description 18
- 239000002994 raw material Substances 0.000 claims abstract description 14
- 235000016623 Fragaria vesca Nutrition 0.000 claims abstract description 10
- 235000011363 Fragaria x ananassa Nutrition 0.000 claims abstract description 10
- AMTWCFIAVKBGOD-UHFFFAOYSA-N dioxosilane;methoxy-dimethyl-trimethylsilyloxysilane Chemical group O=[Si]=O.CO[Si](C)(C)O[Si](C)(C)C AMTWCFIAVKBGOD-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229940083037 simethicone Drugs 0.000 claims abstract description 9
- 239000002562 thickening agent Substances 0.000 claims abstract description 9
- 239000002518 antifoaming agent Substances 0.000 claims abstract description 7
- 239000000839 emulsion Substances 0.000 claims abstract description 7
- 239000001768 carboxy methyl cellulose Substances 0.000 claims abstract description 6
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical group [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims abstract description 5
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims abstract description 5
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims abstract description 5
- 239000000230 xanthan gum Substances 0.000 claims abstract description 5
- 229920001285 xanthan gum Polymers 0.000 claims abstract description 5
- 229940082509 xanthan gum Drugs 0.000 claims abstract description 5
- 235000010493 xanthan gum Nutrition 0.000 claims abstract description 5
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims abstract description 4
- 108010011485 Aspartame Proteins 0.000 claims abstract description 4
- 229920002125 Sokalan® Polymers 0.000 claims abstract description 4
- 239000000605 aspartame Substances 0.000 claims abstract description 4
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims abstract description 4
- 235000010357 aspartame Nutrition 0.000 claims abstract description 4
- 229960003438 aspartame Drugs 0.000 claims abstract description 4
- 229960001631 carbomer Drugs 0.000 claims abstract description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims abstract description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims abstract description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims abstract description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims abstract description 3
- 240000009088 Fragaria x ananassa Species 0.000 claims abstract 2
- 244000185386 Thladiantha grosvenorii Species 0.000 claims description 24
- 235000011171 Thladiantha grosvenorii Nutrition 0.000 claims description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- 238000002360 preparation method Methods 0.000 claims description 7
- 239000011259 mixed solution Substances 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 239000000796 flavoring agent Substances 0.000 claims 2
- 235000019634 flavors Nutrition 0.000 claims 2
- 239000007958 cherry flavor Substances 0.000 claims 1
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 claims 1
- 239000007968 orange flavor Substances 0.000 claims 1
- 239000007967 peppermint flavor Substances 0.000 claims 1
- 235000019658 bitter taste Nutrition 0.000 abstract description 18
- 235000019640 taste Nutrition 0.000 abstract description 5
- 241000220223 Fragaria Species 0.000 description 8
- 210000001035 gastrointestinal tract Anatomy 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 238000011156 evaluation Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 5
- 241000167854 Bourreria succulenta Species 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- 235000019693 cherries Nutrition 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- 239000001116 FEMA 4028 Substances 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 235000006679 Mentha X verticillata Nutrition 0.000 description 2
- 235000002899 Mentha suaveolens Nutrition 0.000 description 2
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 2
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 2
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 2
- 229960004853 betadex Drugs 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000008142 bulk forming laxative Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000013530 defoamer Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000004880 explosion Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 229940117214 magnesium sulfate oral solution Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000001543 purgative effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 235000020374 simple syrup Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Botany (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a magnesium sulfate oral liquid which comprises the following raw materials in percentage by mass: 5 to 40 percent of magnesium sulfate, 0.01 to 1 percent of sweetening agent and 0.01 to 1 percent of essence; the essence is herba Menthae essence, strawberry essence, fructus Citri Tangerinae essence or fructus Pruni Pseudocerasi essence; the defoaming agent is simethicone emulsion; the thickener is sodium carboxymethylcellulose, hydroxypropyl methylcellulose, carbomer or xanthan gum; the sweetener is sucralose or aspartame. According to the invention, the sweetening agent and the essence are added, so that the bitter taste of the magnesium sulfate oral liquid can be reduced, and the taste of the magnesium sulfate oral liquid is improved.
Description
Technical Field
The present invention relates to the field of pharmaceutical formulations. More specifically, the invention relates to a magnesium sulfate oral liquid.
Background
Magnesium sulfate is a bulk purgative, is difficult to be absorbed by the gastrointestinal tract after being orally taken, increases the osmotic pressure in the intestinal cavity, and stimulates the secretion of intestinal juice. At present, bulk laxatives including mannitol, magnesium sulfate, sodium phosphate, polyethylene glycol electrolyte and the like are frequently used for preparing intestinal tracts clinically. The mannitol has obvious stimulation to the gastrointestinal tract, can generate flammable gases such as methane and the like under the action of intestinal bacteria, and has the risk of causing gas explosion when high-frequency electrosurgery is carried out. A plurality of studies prove that the oral magnesium sulfate solution has good intestinal tract preparation effect and small side effect, and can replace the traditional intestinal tract cleaning method. At present, before clinical intravenous pyelography, enteroscopy, gastrointestinal tract operation, gynecological operation and urinary surgery, the oral magnesium sulfate method is commonly used for preparing the intestinal tract.
At present, because magnesium sulfate is bitter and astringent in taste, a part of patients who take the magnesium sulfate in a large amount have adverse reactions such as nausea, vomiting and the like, so that the clinical use of the magnesium sulfate is limited. The preparation needs to be flavored when preparing the magnesium sulfate oral liquid, and the common flavoring method of the oral liquid comprises coating, adopting ion exchange resin, adding bitter blocker, preparing into beta-cyclodextrin inclusion compound and the like. However, the dosage of magnesium sulfate oral preparations is large (generally more than 25g), and the methods are difficult to succeed, such as drug coating, the drug coating is often caused to have a gritty feeling due to the large coated particles, and the beta-cyclodextrin preparation is difficult to successfully coat due to the small magnesium ion, so that a magnesium sulfate oral liquid with low bitter taste is needed.
Disclosure of Invention
An object of the present invention is to solve at least the above problems and to provide at least the advantages described later.
Still another object of the present invention is to provide a magnesium sulfate oral liquid, which can reduce the bitter taste of the magnesium sulfate oral liquid and improve the taste of the magnesium sulfate oral liquid by adding a sweetener and an essence.
To achieve these objects and other advantages in accordance with the present invention, there is provided a magnesium sulfate oral liquid comprising the following raw materials in mass percent: 5 to 40 percent of magnesium sulfate, 0.01 to 1 percent of sweetening agent and 0.01 to 1 percent of essence.
Preferably, the material comprises the following raw materials in percentage by mass: 10 to 17.5 percent of magnesium sulfate, 0.05 to 0.2 percent of sweetening agent and 0.05 to 0.5 percent of essence.
Preferably, the essence is mint essence, strawberry essence, orange essence or cherry essence.
Preferably, the method further comprises the following steps: 0.1 to 5 percent of defoaming agent, wherein the defoaming agent is simethicone emulsion.
Preferably, the defoamer is present in an amount of 0.5% to 2%.
Preferably, the method further comprises the following steps: 0.1-5% of thickening agent, wherein the thickening agent is sodium carboxymethylcellulose, hydroxypropyl methylcellulose, carbomer or xanthan gum.
Preferably, the thickener is 0.5% to 2%.
Preferably, the sweetener is sucralose or aspartame.
Preferably, the sweetener comprises sucralose and momordica grosvenori extract in a mass ratio of 1: 1;
the preparation method of the momordica grosvenori extract comprises the following steps: crushing the momordica grosvenori, adding water with the amount being 2 times of the total mass of the momordica grosvenori into the momordica grosvenori, heating the momordica grosvenori for 3 hours at the temperature of 95-98 ℃, filtering to remove filter residues and removing water to obtain a mixed solution, and decoloring the mixed solution to obtain the momordica grosvenori extract.
The invention at least comprises the following beneficial effects:
firstly, the bitter taste of the magnesium sulfate oral liquid can be reduced by adding the sweetening agent and the essence, the taste of the magnesium sulfate oral liquid is improved, and compared with the prior art that the magnesium sulfate oral liquid is prepared by adopting simple syrup (which cannot be used by single-syrup diabetes patients), the magnesium sulfate oral liquid adopts sucralose for not influencing the use of the diabetes patients.
Secondly, the defoaming agent simethicone is added into the magnesium sulfate oral liquid, so that the definition of the visual field during enteroscopy can be further improved, the bubble interference can be reduced, the enteroscopy effect can be improved, and the bitter taste of the magnesium sulfate oral liquid can be effectively reduced by adding the thickening agent.
Thirdly, the momordica grosvenori extract is added into the magnesium sulfate oral liquid, and the momordica grosvenori extract contains rich sweet glycosides, a small amount of D-mannitol and other components, so that the use of sucralose can be effectively reduced.
Additional advantages, objects, and features of the invention will be set forth in part in the description which follows and in part will become apparent to those having ordinary skill in the art upon examination of the following or may be learned from practice of the invention.
Detailed Description
The present invention is further described in detail below with reference to examples so that those skilled in the art can practice the invention with reference to the description.
< example 1>
The magnesium sulfate oral liquid comprises the following components: 5g of magnesium sulfate, 0.01g of sucralose, 0.01g of mint essence, 94.78g of water, 0.1g of simethicone emulsion (40mg/ml) and 0.1g of sodium carboxymethylcellulose.
< example 2>
The magnesium sulfate oral liquid comprises the following components: 40g of magnesium sulfate, 1g of sucralose, 1g of orange essence, 48g of water, 5g of simethicone and 5g of sodium carboxymethylcellulose.
< example 3>
The magnesium sulfate oral liquid comprises the following components: 10g of magnesium sulfate, 0.05g of sucralose, 0.05g of strawberry essence, 88.9g of water, 0.5g of simethicone emulsion (40mg/ml) and 0.5g of carboxymethyl cellulose.
< example 4>
The magnesium sulfate oral liquid comprises the following components: 17.5g of magnesium sulfate, 0.2g of sucralose, 0.5g of cherry essence, 71.8g of water, 5g of simethicone emulsion (40mg/ml) and 5g of carbomer.
< example 5>
The magnesium sulfate oral liquid comprises the following raw materials in parts by weight: 25g of magnesium sulfate, 0.1g of sucralose, 0.3g of strawberry essence and 174.6g of water.
< example 6>
The magnesium sulfate oral liquid comprises the following raw materials in parts by weight: 25g of magnesium sulfate, 0.1g of aspartame, 0.3g of strawberry essence and 174.6g of water.
< example 7>
The magnesium sulfate oral liquid comprises the following raw materials in parts by weight: 35g of magnesium sulfate, 0.2g of sucralose, 0.3g of strawberry essence and 164.5g of water.
< example 8>
The magnesium sulfate oral liquid comprises the following raw materials in parts by weight: 35g of magnesium sulfate, 0.2g of sucralose, 0.3g of strawberry essence and 64.5g of water.
< example 9>
The magnesium sulfate oral liquid comprises the following raw materials in parts by weight: 35g of magnesium sulfate, 0.2g of sucralose, 0.3g of strawberry essence and 264.5g of water.
< example 10>
The magnesium sulfate oral liquid comprises the following raw materials in parts by weight: 35g of magnesium sulfate, 0.2g of sucralose, 0.3g of cherry essence, 162.1g of water and 2.4g of simethicone emulsion (40 mg/ml).
< example 11>
The magnesium sulfate oral liquid comprises the following raw materials in parts by weight: 35g of magnesium sulfate, 0.2g of sucralose, 0.3g of cherry essence, 163.5g of water and 1g of xanthan gum.
< example 12>
The magnesium sulfate oral liquid comprises the following raw materials in parts by weight: 35g of magnesium sulfate, 0.2g of sweetening agent, 0.3g of strawberry essence and 164.5g of water;
wherein the sweetener comprises sucralose and a momordica grosvenori extract in a mass ratio of 1: 1;
the preparation method of the momordica grosvenori extract comprises the following steps: crushing the momordica grosvenori, adding water with the amount being 2 times of the total mass of the momordica grosvenori into the momordica grosvenori, heating the momordica grosvenori for 3 hours at the temperature of 95-98 ℃, filtering to remove filter residues and removing water to obtain a mixed solution, and decoloring the mixed solution to obtain the momordica grosvenori extract.
< comparative example 1>
The magnesium sulfate oral liquid comprises the following raw materials in parts by weight: 35g of magnesium sulfate and 165g of water.
< characterization of Experimental results >
1. Preparing a magnesium sulfate oral liquid according to the components of example 5, examples 7 to 9, examples 11 to 12 and comparative example 1;
2. evaluation test of bitterness
2.1, grouping the 8 groups of magnesium sulfate oral liquids, wherein the first group comprises: example 8, example 9, second group: example 7 example 8, third group: example 7 and example 11, fourth group: example 11, example 12, fifth group: example 7 and comparative example 1, sixth group: example 5 and example 7;
2.2 and 11 healthy subjects try five groups of magnesium sulfate oral liquids respectively, and the trying method comprises the following steps: each person pours 10ml of magnesium sulfate oral solution into oral cavity each time, and sips mouth for about 1min without swallowing, senses the bitter taste of the solution, spits out the magnesium sulfate solution and gargles. The evaluation method comprises the following steps: after each subject tries a group of the magnesium sulfate oral liquids, the bitter taste of the magnesium sulfate oral liquids in the group is compared, for the same group of the magnesium sulfate oral liquids, the same evaluation which is more than or equal to six of the evaluation results of 11 subjects is the final evaluation result of the group of the magnesium sulfate oral liquids, and the results are shown in table 1;
table 1 shows bitterness evaluation
The results show that the analysis of the first and second experiments can result in increased water usage and reduced bitter taste of the magnesium sulfate oral liquid;
the third group of experiments can be analyzed to obtain that the bitter taste of the magnesium sulfate oral liquid can be reduced by adding the thickening agent xanthan gum;
the fourth group of experiments are analyzed to obtain that the bitter taste of the magnesium sulfate oral liquid can be reduced by adding the momordica grosvenori extract;
the fifth group of experiments are analyzed to obtain the magnesium sulfate oral liquid which is added with the sweetener and the essence to obviously improve the taste of the magnesium sulfate oral liquid compared with the magnesium sulfate oral liquid without the sweetener and the essence;
the sixth experiment group is analyzed to show that the bitter taste of the magnesium sulfate oral liquid can be effectively reduced by increasing the amount of the sweetening agent;
based on the above experiment, it can be found that the bitter taste of example 12, example 11, example 7 and comparative example 1 is enhanced in order and that example 12 has almost no bitter taste.
The results of scoring the magnesium sulfate oral liquids according to example 5, examples 7 to 9, examples 11 to 12, and comparative example 1 by 2.3 and 11 subjects are shown in table 2, wherein 0 to 10 indicate that the bitterness is increased in order, and 0 indicates that the bitterness is not decreased;
table 2 gives the bitterness score
While embodiments of the invention have been described above, it is not limited to the applications set forth in the description and the embodiments, which are fully applicable to various fields of endeavor for which the invention may be embodied with additional modifications as would be readily apparent to those skilled in the art, and the invention is therefore not limited to the details given herein and to the embodiments shown and described without departing from the generic concept as defined by the claims and their equivalents.
Claims (9)
1. The magnesium sulfate oral liquid is characterized by comprising the following raw materials in percentage by mass: 5 to 40 percent of magnesium sulfate, 0.01 to 1 percent of sweetening agent and 0.01 to 1 percent of essence.
2. The magnesium sulfate oral liquid of claim 1, comprising the following raw materials in percentage by mass: 10 to 17.5 percent of magnesium sulfate, 0.05 to 0.2 percent of sweetening agent and 0.05 to 0.5 percent of essence.
3. The magnesium sulfate oral liquid of claim 2, wherein the flavor is peppermint flavor, strawberry flavor, orange flavor, or cherry flavor.
4. The magnesium sulfate oral liquid of claim 1 further comprising: 0.1 to 5 percent of defoaming agent, wherein the defoaming agent is simethicone emulsion.
5. The magnesium sulfate oral liquid of claim 4 wherein the amount of antifoaming agent is 0.5% to 2%.
6. The magnesium sulfate oral liquid of claim 1 further comprising: 0.1-5% of thickening agent, wherein the thickening agent is sodium carboxymethylcellulose, hydroxypropyl methylcellulose, carbomer or xanthan gum.
7. The magnesium sulfate oral liquid of claim 6 wherein the thickener is 0.5% to 2%.
8. The magnesium sulfate oral liquid of claim 1, wherein the sweetener is sucralose or aspartame.
9. The magnesium sulfate oral liquid of claim 1, wherein the sweetener comprises sucralose and luo han guo extract in a mass ratio of 1: 1;
the preparation method of the momordica grosvenori extract comprises the following steps: crushing the momordica grosvenori, adding water with the amount being 2 times of the total mass of the momordica grosvenori into the momordica grosvenori, heating the momordica grosvenori for 3 hours at the temperature of 95-98 ℃, filtering to remove filter residues and removing water to obtain a mixed solution, and decoloring the mixed solution to obtain the momordica grosvenori extract.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911030657.1A CN110652527A (en) | 2019-10-28 | 2019-10-28 | Magnesium sulfate oral liquid |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911030657.1A CN110652527A (en) | 2019-10-28 | 2019-10-28 | Magnesium sulfate oral liquid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110652527A true CN110652527A (en) | 2020-01-07 |
Family
ID=69041872
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911030657.1A Pending CN110652527A (en) | 2019-10-28 | 2019-10-28 | Magnesium sulfate oral liquid |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110652527A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111494313A (en) * | 2020-05-25 | 2020-08-07 | 李会芳 | Enema for treating sow constipation and preparation method thereof |
| CN118178464A (en) * | 2024-03-28 | 2024-06-14 | 南方医科大学珠江医院 | A method for treating macrophage damage caused by important mediators of sepsis |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102196734A (en) * | 2008-10-28 | 2011-09-21 | 大塚制药株式会社 | Low-calorie beverage composition containing luo han guo extract and sucralose |
| CN104257686A (en) * | 2014-09-19 | 2015-01-07 | 四川海思科制药有限公司 | Pharmaceutical composition with compound of sodium sulfate, potassium sulfate and magnesium sulfate as well as preparation method and application of pharmaceutical composition |
-
2019
- 2019-10-28 CN CN201911030657.1A patent/CN110652527A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102196734A (en) * | 2008-10-28 | 2011-09-21 | 大塚制药株式会社 | Low-calorie beverage composition containing luo han guo extract and sucralose |
| CN104257686A (en) * | 2014-09-19 | 2015-01-07 | 四川海思科制药有限公司 | Pharmaceutical composition with compound of sodium sulfate, potassium sulfate and magnesium sulfate as well as preparation method and application of pharmaceutical composition |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111494313A (en) * | 2020-05-25 | 2020-08-07 | 李会芳 | Enema for treating sow constipation and preparation method thereof |
| CN118178464A (en) * | 2024-03-28 | 2024-06-14 | 南方医科大学珠江医院 | A method for treating macrophage damage caused by important mediators of sepsis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101553719B1 (en) | Liquid compositions of calcium acetate | |
| CN109908142B (en) | Bowel cleansing composition | |
| WO2019076066A1 (en) | Bitter ganoderma lucidum spore powder and preparation method thereof | |
| CN110652527A (en) | Magnesium sulfate oral liquid | |
| EP2598123A1 (en) | Compositions | |
| US11471472B2 (en) | Use of verbascoside in preparation of drug for preventing or treating glomerular podocyte injured renal disease | |
| CN101869611A (en) | Admixture capable of repelling chicken coccidiosis and stopping dysentery and preparation method thereof | |
| JP2005170837A (en) | Seaweed extract and saccharide hydrolase inhibitor containing the same | |
| CN104288344B (en) | Application of Pu' er tea extract in preparation of medicine or food for regulating intestinal flora and relaxing bowels | |
| CN101874842B (en) | Chinese patent medicament for treating reflux esophagitis and preparation method thereof | |
| CN105920394A (en) | Fruit-flavored lung clearing and phlegm eliminating gel for children and preparation method of gel | |
| WO2022055287A1 (en) | Supplementary bowel-cleansing beverage | |
| JPH05255126A (en) | Bitterness reduction composition | |
| CN116211798A (en) | Hydroxychloroquine sulfate oral solution and preparation method thereof | |
| CN110314134B (en) | Auxiliary water for gastrointestinal endoscopy and preparation method thereof | |
| CN100531714C (en) | Preparation method for producing concentrated Shuanghuanglian oral liquid | |
| JP4950551B2 (en) | Gastrointestinal mucosa protective agent | |
| CN113558558A (en) | Method for improving definition of mucous membrane under gastroscope | |
| KR100370391B1 (en) | Pharmaceutical composition for oral administration having therapeutic activity on gastrointestinal disorders | |
| CN114903960B (en) | Traditional Chinese medicine composition for treating chronic gastritis and preparation method thereof | |
| JP7646740B2 (en) | Stomach discomfort relief and urinary suppressant | |
| CN119033855B (en) | A Chinese medicine compound oral liquid for moistening intestines and relieving constipation and preparation method thereof | |
| CN101991723B (en) | A kind of Shiqi exogenous Chinese medicine oral liquid | |
| CN115813981B (en) | Traditional Chinese medicine composition and medicine with function of preventing and repairing dental ulcer, and preparation method and application thereof | |
| CN101176737A (en) | Pharmaceutical composition of chicken bile and preparation thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200107 |